Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 942-401-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with national standard methods with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 994
- Report date:
- 1995
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- GLP compliance:
- not specified
- Type of assay:
- in vitro mammalian chromosome aberration test
Test material
- Reference substance name:
- Bismuth vanadium tetraoxide
- EC Number:
- 237-898-0
- EC Name:
- Bismuth vanadium tetraoxide
- Cas Number:
- 14059-33-7
- Molecular formula:
- BiO4V
- IUPAC Name:
- bismuth; oxygen(2-); vanadium
- Details on test material:
- - Name of test material (as cited in study report): Bismuth Vanadate
- Molecular formula (if other than submission substance): BiVO4
- Molecular weight (if other than submission substance): 323.92
- Physical state: yellow powder
- Analytical purity: >99.5% w/w
- Impurities (identity and concentrations): water and others, <0.5% w/w
- Lot/batch No.: BVB-1018
- Stability under test conditions: stable
- Other: melting point>800°C
Constituent 1
Method
- Target gene:
- not applicable
Species / strain
- Species / strain / cell type:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9-mix from treated SD rats
- Test concentrations with justification for top dose:
- 0, 313, 625, and 1250 µg/ml without S9-mix and 0, 1250, 2500 and 5000 µg/ml with S9-mix
- Vehicle / solvent:
- - Solvent used: CMC (carboxymethyl cellulose), 0.5%
Controls
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: MMC without S9-mix, MMC and CPA with S9-mix
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: 24 or 48 hours without metabolic activation, 6 hours with metabolic activation
SPINDLE INHIBITOR (cytogenetic assays): colcemide
NUMBER OF CELLS EVALUATED: 100-200
DETERMINATION OF CYTOTOXICITY
- Method: mitotic index; relative total growth - Evaluation criteria:
- not tranlated from japanese
- Statistics:
- not reported
Results and discussion
Test results
- Species / strain:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Remarks:
- In every test under all concentration range, the test substance did not induce any chromosome aberration, i.e. polyploidy and structural (see Table2)
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- see Table 1
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
Any other information on results incl. tables
Table 1: Cell growth index
Without metabolic activation |
With metabolic activation |
||||||||||
|
Concen-tration (µg/ml) |
Cell growth index (%) |
Frequency of mitotic cells |
Frequency of aberration cells (50 cells) |
|
Concentra-tion (µg/ml) |
Cell growth index (%) |
Frequency of mitotic cells |
Frequency of aberration cells (50 cells) |
||
Polyploid |
Structural |
Polyploid |
Structural |
||||||||
24 hours treatment |
0 |
100 |
++ |
0 |
0 |
+ S9 mix |
0 |
100 |
++ |
0 |
0 |
39.1* |
92.1 |
++ |
2 |
0 |
625* |
91.9 |
++ |
2 |
0 |
||
78.1* |
90.5 |
++ |
0 |
0 |
1250* |
93.8 |
++ |
4 |
0 |
||
156* |
75.5 |
++ |
0 |
0 |
2500* |
97.5 |
++ |
2 |
2 |
||
313* |
67.6 |
++ |
0 |
0 |
5000* |
92.5 |
++ |
4 |
0 |
||
625* |
51.9 |
++ |
0 |
0 |
X |
X |
X |
X |
X |
||
1250* |
41.5 |
+ |
2 |
0 |
X |
X |
X |
X |
X |
||
2500* |
39.8 |
± |
X |
X |
X |
X |
X |
X |
X |
||
5000* |
46.9 |
- |
X |
X |
X |
X |
X |
X |
X |
||
48 hours treatment |
0 |
100 |
++ |
0 |
0 |
-S9 mix |
0 |
100 |
++ |
0 |
0 |
156* |
93.3 |
++ |
0 |
0 |
625* |
85.4 |
++ |
0 |
0 |
||
313* |
84.2 |
++ |
0 |
0 |
1250* |
81.7 |
++ |
0 |
0 |
||
625* |
62.3 |
++ |
0 |
0 |
2500* |
82.3 |
++ |
4 |
0 |
||
1250* |
34.4 |
+ |
4 |
0 |
5000* |
36.6 |
++ |
0 |
2 |
||
2500* |
23.2 |
- |
X |
X |
X |
X |
X |
X |
X |
||
5000* |
25.2 |
- |
X |
X |
X |
X |
X |
X |
X |
||
*Average of 2 plates; ++Many mitotic cells; +Small amount of mitotic cells; ±Very small amount of mitotic cells; -No mitotic cells |
Table 2: Results of chromosomal aberration test (without metabolic activation)
Treatment |
Treatment time (h) |
Concentration (µl/ml) |
Total observe (100+100) |
Total number of polyploids |
Judg-ment |
Number and percentage (%) of cells showing chromosomal aberrarions |
||||||||
Gap |
Chromatid-type |
Chromodome-type |
Others |
Total |
Judg-ment |
|||||||||
g |
ctb |
cte |
csb |
cse |
-g |
+g |
||||||||
Solvent (0.5% CMC) |
24 |
0 |
200 |
1 (0.5) |
|
0 (0.0) |
0 (0.0) |
1 (0.5) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
1 (0.5) |
1 (0.5) |
|
48 |
0 |
200 |
0 (0.0) |
|
0 (0.0) |
0 (0.0) |
1 (0.5) |
0 (0.0) |
1 (0.5) |
0 (0.0) |
2 (1.0) |
2 (1.0) |
|
|
Test substance |
24 |
313* |
200 |
1 (0.5) |
- |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
- |
625* |
200 |
2 (1.0) |
- |
0 (0.0) |
0 (0.0) |
1 (0.5) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
1 (0.5) |
1 (0.5) |
- |
||
1250* |
200 |
5 (2.5) |
- |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
1 (0.5) |
0 (0.0) |
1 (0.5) |
1 (0.5) |
- |
||
48 |
313* |
200 |
2 (1.0) |
- |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
1 (0.5) |
0 (0.0) |
1 (0.5) |
1 (0.5) |
- |
|
625* |
200 |
4 (2.0) |
- |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
- |
||
1250* |
200 |
5 (2.5) |
- |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
1 (0.5) |
0 (0.0) |
1 (0.5) |
1 (0.5) |
- |
||
Positive control (MMC) |
24 |
0.05 |
200 |
1 (0.5) |
- |
2 (1.0) |
17 (8.5) |
54 (27.0) |
0 (0.0) |
1 (0.5) |
0 (0.0) |
69(34.5) |
71(35.5) |
++ |
48 |
0.05 |
200 |
3 (1.5) |
- |
7 (3.5) |
16 (8.0) |
98 (49.0) |
2 (1.0) |
7 (3.5) |
0 (0.0) |
114(57.0) |
119(59.5) |
+++ |
|
Fill in the number of cells observed, polyploids and cells showing total structural chromosomal aberrations in 2 plates, and the percentage (%) of cells showing aberrations in parenthesis with every concentration of treatment. Gap (g) – Fill in the total value of chromatd-type and chromosome-type. Sum total (-g) – Fill in the total number and percentage of cells except those which has only gaps. If there are many aberrations in one cell, calculate that cell as one cell showing aberrations. For example, if there are 2 exchanges in one cell, calculate that cell as one showing aberrations. One cell showing break and one cell showing exchange. ctb: chomatid break; cte: chromatid exchange; cse: chromosome exchange; others: fragmentation etc. (except pulverization) |
Applicant's summary and conclusion
- Conclusions:
- The test substance bismuth vanadate was not cytogenic in the in vitro chromosome aberration test with Chinese hamster lung fibroblasts, both with and without metabolic activation, when tested up to cytotoxic concentrations.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.